Zymeworks
✦ Quant Ownership Signal how this is computed
- The number of reporting institutions decreased by 5 in the most recent period (2026/Q3).
- Total institutional ownership rose 2.7 percentage points.
Ownership vs. money flow
DivergingInstitutions added shares last reporting period, and the stock has seen net outflows in main-fund flow over the last 20 trading sessions - the two are pointing in different directions.
Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.
Institutional ownership
- Held by institutions
- 101.12% +2.70pp
- Institutions
- 253 -5
- As of
- 2026/Q3 vs. prior period
Holder types
Top holders as of 2026-10-21
Bar length is relative to the largest holder shown here, not to 100% of the company.
Insiders
50 filings tracked · 31 buys · 4 sells
| Name | Role | Stake |
|---|---|---|
| EcoR1 Capital, LLC | -- | 33.28% |
| Gregory Ciongoli | Independent Director | 0.71% |
| Kenneth Galbraith | Chairperson & CEO | 0.33% |
| Mark Hollywood | Chief Operating Officer | 0.19% |
| Paul Moore | Chief Scientific Officer | 0.07% |
| Adam Schayowitz | Executive VP and Head of Research & Development | 0.03% |
| Jeffrey T. Smith | -- | 0.03% |
| Troy Cox | Former Independent Director | 0.01% |
| Leone Patterson | Former Executive VP and Chief Business & Financial Officer | 0.00% |
| Brian Cherry | Independent Director | -- |
| Nancy Davidson | Director | -- |
Insider transactions most recent Form 4 filings
| Date | Name | Role | Type | Shares | Price |
|---|---|---|---|---|---|
| 2026-10-08 | Adam Schayowitz | Executive VP and Head of Research & Development | Derivative Exercise and Sale | -13,832 | $25.85 |
| 2026-10-08 | Adam Schayowitz | Executive VP and Head of Research & Development | Derivative Exercise and Retained | +23,205 | -- |
| 2026-07-05 | Mark Hollywood | Chief Operating Officer | Other Acquisition | +939 | $22.22 |
| 2026-05-12 | Paul Schneider | Executive Vice President | Other Derivative Acquisition | +119,000 | -- |
| 2026-05-12 | Paul Schneider | Executive Vice President | Other Derivative Acquisition | +178,000 | $24.57 |
| 2026-05-12 | Paul Schneider | Executive Vice President | Initial Statement of Beneficial | 0 | -- |
| 2026-04-08 | Adam Schayowitz | Executive VP and Head of Research & Development | Other Derivative Acquisition | +47,000 | -- |
| 2026-04-08 | Adam Schayowitz | Executive VP and Head of Research & Development | Other Derivative Acquisition | +70,000 | $27.35 |
| 2026-04-08 | Adam Schayowitz | Executive VP and Head of Research & Development | Other Derivative Acquisition | +76,000 | -- |
| 2026-04-08 | Adam Schayowitz | Executive VP and Head of Research & Development | Initial Statement of Beneficial | 0 | -- |
| 2026-04-08 | Scott Platshon | Executive VP & Chief Business Officer | Other Derivative Acquisition | +47,000 | -- |
| 2026-04-08 | Scott Platshon | Executive VP & Chief Business Officer | Other Derivative Acquisition | +70,000 | $27.35 |
| 2026-04-08 | Scott Platshon | Executive VP & Chief Business Officer | Other Derivative Acquisition | +76,000 | -- |
| 2026-04-08 | Scott Platshon | Executive VP & Chief Business Officer | Initial Statement of Beneficial | 0 | -- |
| 2026-04-05 | Kristin Stafford | Chief Financial Officer | Other Derivative Acquisition | +169,000 | -- |
| 2026-04-05 | Kristin Stafford | Chief Financial Officer | Other Derivative Acquisition | +178,000 | $25.84 |
| 2026-03-31 | Kristin Stafford | Chief Financial Officer | Initial Statement of Beneficial | 0 | -- |
| 2026-01-31 | Sabeen Mekan | Senior VP & Chief Medical Officer | Initial Statement of Beneficial | 0 | -- |
| 2026-01-11 | Kenneth Galbraith | Chairperson & CEO | Derivative Exercise and Sale | -30,424 | $22.67 |
| 2026-01-11 | Kenneth Galbraith | Chairperson & CEO | Other Derivative Acquisition | +144,000 | -- |
Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.
Quote time 2026-11-20 19:30:06 · For reference only, not investment advice and not tailored to your situation.
Zymeworks discussion 0 comments